October 2023 in “Microorganisms” Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
25 citations,
January 2022 in “Endocrine journal” Long COVID patients may have hormonal imbalances linked to their symptoms.
52 citations,
January 2022 in “Current Research in Pharmacology and Drug Discovery” New treatments for COVID-19 show promise, but more effective antiviral drugs are needed.
June 2022 in “Organic communications” Natural compounds, especially Withaferin-A, may help treat post-COVID-19 complications, but some may have side effects.
4 citations,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
6 citations,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
16 citations,
September 2020 in “British journal of dermatology/British journal of dermatology, Supplement” The article suggests that targeting specific immune pathways could help control and treat the skin disease hidradenitis suppurativa.
3 citations,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
January 2024 in “Journal der Deutschen Dermatologischen Gesellschaft” Non-biologic immunosuppressive drugs are crucial for treating autoimmune and chronic inflammatory skin diseases.
March 2024 in “Research Square (Research Square)” Scalp cooling therapy helps preserve hair during chemotherapy for most patients.
November 2008 in “Journal of Generic Medicines” The document updates on EU legal changes, including pharmaceutical patents, class actions in Italy, and various drug-related rulings.
10 citations,
November 2018 in “Nature Biotechnology” Drugmakers are optimistic about targeting the Wnt pathway for new treatments despite past challenges.
1 citations,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
51 citations,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
8 citations,
June 2011 in “Nature Biotechnology” Stem cell treatments can potentially treat baldness, with one trial showing hair growth after injecting a hair-stimulating complex, and no safety issues were reported.
3 citations,
August 2014 in “Journal of The American Academy of Dermatology” Filaggrin mutations are linked to atopic dermatitis and help explain how genetics and environment affect the disease.
176 citations,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
3 citations,
November 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Entrepreneurial companies are key to advancing dermatology treatments and patient care.
1 citations,
June 2017 in “International Journal of Toxicology” Most drugs fail to reach the market, but understanding their properties and using strategies like early toxicity tests and drug repurposing can help advance their development.
September 2013 in “Experimental Dermatology” The document concluded that stem cells are crucial for skin repair, regeneration, and may help in developing advanced skin substitutes.
224 citations,
March 2006 in “Seminars in Cutaneous Medicine and Surgery” The document concludes that understanding hair follicle biology can lead to better hair loss treatments.
182 citations,
November 2017 in “Molecular Aspects of Medicine” The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.
141 citations,
September 2016 in “European Journal of Dermatology” Taxane chemotherapy can cause skin, hair, and nail side effects, which are often under-reported and can affect patient quality of life.
72 citations,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
68 citations,
November 2015 in “The Journal of Allergy and Clinical Immunology” Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
65 citations,
January 2013 in “Cochrane library” Some systemic treatments work for nail psoriasis but can have serious side effects.
44 citations,
September 2015 in “Annals of Oncology” Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
42 citations,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
33 citations,
April 2011 in “Journal of Veterinary Internal Medicine” Long-term fluticasone treatment does not harm the immune system in horses with heaves.
26 citations,
October 2007 in “Experimental Dermatology” L-Carnitine-L-tartrate may help hair grow and prevent hair loss.